Seqens, a CDMO of small-molecule active pharmaceutical ingredients (APIs), intermediates, and specialty ingredients, is entering the cell- and gene-therapy market via a key acquisition. Pierre Luzeau, CEO, Seqens, provided the details at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

In December 2023, Seqens finalized its acquisition of CELLforCURE, a a Les Ulis, France-based CDMO of cell and gene therapies, from Novartis. Inaugurated 10 years ago in September 2013, the CELLforCURE by Seqens site was one of the first modular units in Europe to enable large-scale industrial production of advanced therapy medicinal products (ATMPs).

Key details of the facility acquired: 

• 2 200 square meters of GMP production area 
• Six equipped production suites (+ one unequipped) 
• Commercial autologous CAR-T manufacturing (up to 2 batches/day) historical track record
• 10  years of experience in cell & gene therapy with a cross-functional team of experts